Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Ireland / NCT01840293
Recruiting Observational

Breast Cancer Proteomics and Molecular Heterogeneity

NCT01840293 · tracked via the Priya Life Science Ireland tracker
Sponsor
Cancer Trials Ireland
Phase
Observational
Started
2013-02
Last updated
2025-12-19

Condition(s) studied

Primary Breast CancerRecurrent/Metastatic Breast Cancer

Study summary

Primary objective:

The primary objective is to define the proteomic and molecular characteristics of primary and recurrent/ metastatic breast tumours with special focus on the expression of S100 protein and the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) genes

Secondary objective:

* To expand our understanding of the complex molecular pathways dictating the progression of breast cancer and their response to different treatment regimes.
* To relate proteomic findings to survival data
* To identify potential serum markers of breast cancer progression

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Patients diagnosed with primary breast cancer attending hospital for the resection of their tumour tissue Or -Patients with suspected or confirmed recurrent or metastatic breast cancer (Patient has a history of a biopsy- or surgically- (i.e. pathologically) confirmed primary breast cancer) attending hospital for the resection/biopsy and/or treatment of tumour tissue Or -Patient with suspected (but not necessarily biopsy confirmed) newly diagnosed stage 4 breast cancer attending hospital for the resection/biopsy and/or treatment of their tumour tissue 2. Patients receiving neoadjuvant treatment are also eligible (if applicable) 3. Patients have to be ≥ 18 years of age 4. Patients must be able to give informed consent

Primary outcome measure(s)

  • Investigation of proteins and their pathways in primary breast cancer — 10 years
    Investigation of proteins and their pathways in primary breast cancer, which are associated with patient outcome.

Trial sites (6)

FacilityCityRegionStatus
Cork University Hospital Cork Ireland Recruiting
Beaumont Hospital Dublin Ireland Recruiting
St James's Hospital Dublin Ireland Completed
St. Vincent's University Hospital Dublin Ireland Recruiting
University Hospital Limerick Limerick Ireland Active Not Recruiting
University Hospital Waterford Waterford Ireland Recruiting

More Cancer Trials Ireland trials in Ireland

Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas) Recruiting
TAILORx Tissue Bank Active, not recruiting
'SOURCE - LUNG' Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours (SOURCE Lung) Recruiting
Spine SABR - Dose-escalated Stereotactic Ablative Body Radiotherapy (SABR) for Solid Tumour Spine Metastases Recruiting
Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01840293 on ClinicalTrials.gov ↗ ← All trials in Ireland